Organon & Co (NYSE: OGN) is a global healthcare company that develops and sells prescription medicines and biosimilars across women's health and general medicines. Revenue comes from transactional product sales through drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers including health maintenance organizations and pharmacy benefit managers. The company markets a portfolio of over 70 products in more than 140 countries and territories, with key branded products including Nexplanon (etonogestrel implant, sold as Implanon NXT outside the United States) and NuvaRing in the contraception segment of its women's health portfolio. Manufacturing is conducted across six company-owned facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom, as disclosed in the FY2025 10-K filed February 24, 2026. The portfolio spans two primary segments: women's health (contraception and fertility therapeutic areas) and general medicines, which includes biosimilars.

Revenue model

Transactional product sales of prescription medicines and biosimilars sold through drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers.

Products and services

Portfolio of over 70 products including: Women's Health brands Nexplanon (etonogestrel implant, also sold as Implanon NXT outside the United States) and NuvaRing (etonogestrel/ethinyl estradiol); general medicines; and biosimilars. (Per FY2025 10-K, filed 2026-02-24.)

Customers and end markets

Drug wholesalers and retailers, hospitals, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutional healthcare providers across more than 140 countries and territories.

Value-chain role

Pharmaceutical manufacturer and commercial seller of branded prescription medicines and biosimilars. Operates six manufacturing facilities (Belgium, Brazil, Indonesia, Mexico, Netherlands, United Kingdom) and handles its own commercial distribution through channel partners.

Geographic exposure

Products sold in over 140 countries and territories. Manufacturing presence in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. (Per FY2025 10-K, filed 2026-02-24.)

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: Bristol-Myers Squibb Co Catalent, Inc. CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Intra-Cellular Therapies, Inc. Johnson & Johnson Royalty Pharma PLC Viatris Inc Zoetis Inc